The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...
The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...
Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...
Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...
MRI-invisible prostate lesions. It sounds like the stuff of science fiction and fantasy, a creation from the minds of H.G. Wells, who wrote The Invisible Man, or J.K. Rowling, who authored the ...
US FDA grants fast track designation to Clarity Pharma’s Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer: Sydney, Australia Monday, January 27, 2025, 14:00 Hrs [I ...
Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...
Quibim says its longer-term plan is to create digital twins of the entire human body, serving “dynamic models” that help the ...
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback